Cover Image
市場調查報告書

纖維母細胞生長因子2:開發中產品分析

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 364846
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
纖維母細胞生長因子2:開發中產品分析 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 56 Pages
簡介

本報告提供以纖維母細胞生長因子2為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

纖維母細胞生長因子2概要

治療藥的開發

纖維母細胞生長因子2:開發中的產品 - 各開發階段

纖維母細胞生長因子2:開發中的產品 - 各治療範圍

纖維母細胞生長因子2:開發中的產品 - 各適應症

纖維母細胞生長因子2:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

纖維母細胞生長因子2:企業開發中的產品

纖維母細胞生長因子2:大學/機關開發中的產品

纖維母細胞生長因子2:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

纖維母細胞生長因子2治療藥的開發企業

  • F. Hoffmann-La Roche Ltd.
  • Kringle Pharma, Inc.
  • Momenta Pharmaceuticals, Inc.
  • Ohr Pharmaceutical Inc.
  • Progen Pharmaceuticals Limited
  • Ribomic Inc.

藥物簡介

纖維母細胞生長因子2:暫停中的計劃

纖維母細胞生長因子2:開發中止的產品

纖維母細胞生長因子2:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0977TDB

Summary:

According to the recently published report 'Fibroblast Growth Factor 2 - Pipeline Review, H2 2017'; Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family. This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. Diseases associated with FGF2 include corneal neovascularization and pulmonary capillary hemangiomatosis.

The report 'Fibroblast Growth Factor 2 - Pipeline Review, H2 2017' outlays comprehensive information on the Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Metabolic Disorders, Ophthalmology, Central Nervous System, Immunology and Musculoskeletal Disorders which include indications Critical Limb Ischemia, Achondroplasia, Age Related Macular Degeneration, Bone Disorders, Breast Cancer, Cancer Pain, Diabetic Macular Edema, Fibrosis, Hepatocellular Carcinoma, Intermittent Claudication, Melanoma, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Proliferative Diabetic Retinopathy (PDR), Prostate Cancer, Retinal Vein Occlusion, Rheumatoid Arthritis, Solid Tumor and Wet (Neovascular / Exudative) Macular Degeneration.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
  • The report reviews Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Overview
    • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Companies Involved in Therapeutics Development
    • ID Pharma Co Ltd
    • Kringle Pharma Inc
    • Ohr Pharmaceutical Inc
    • Ribomic Inc
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drug Profiles
    • Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-400P - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DVC-10101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein to Inhibit FGF-2 for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NK-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oncolytic Virus to Activate FGF2 for Pancreatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBM-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • squalamine lactate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TR-764 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Dormant Products
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Discontinued Products
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 10, 2017: Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD
      • May 02, 2016: Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee
      • Apr 27, 2016: Ohr Pharmaceutical Announces Presentation on Squalamine Lactate at the 2016 Association for Research in Vision and Ophthalmology Conference in Seattle, WA
      • Apr 18, 2016: Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program
      • Mar 29, 2016: Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program
      • Nov 16, 2015: Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual Meeting
      • Nov 12, 2015: Ohr Pharmaceutical Announces Submission of a Special Protocol Assessment and Upcoming Presentation on OHR-102 at American Academy of Ophthalmology
      • Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion
      • May 07, 2015: Ohr Pharmaceutical Presents Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference
      • Apr 30, 2015: Ohr Pharmaceutical to Present at the 2015 Association for Research in Vision and Ophthalmology Conference in Denver, CO
      • Mar 27, 2015: Ohr Pharmaceutical Announces Final Topline Data From OHR-102 Phase II IMPACT Study in Wet-AMD
      • Mar 02, 2015: Ohr Pharmaceutical Announces Additional Positive Anatomic Data From the OHR-102 IMPACT Study Interim Analysis Presented at Annual Macula Society Meeting
      • Oct 20, 2014: Ohr Pharmaceutical Announces New Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study Presented at the 2014 American Academy of Ophthalmology Scientific Meeting
      • Oct 14, 2014: Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD
      • Oct 07, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the 2014 American Academy of Ophthalmology Scientific Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by ID Pharma Co Ltd, H2 2017
  • Pipeline by Kringle Pharma Inc, H2 2017
  • Pipeline by Ohr Pharmaceutical Inc, H2 2017
  • Pipeline by Ribomic Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top